May 26, 2014
Three sodium-glucose co-transporter-2 (SGLT-2) inhibitors under four brands hit the Japanese market on May 23 upon their NHI price listing, opening up a battle with Astellas Pharma’s first-in-class Suglat (ipragliflozin) in the likely crowded but lucrative marketplace. All three compounds...read more